方法对比
并排查看您选择的方法；存在差异的行会高亮显示。
| PRISMA：系统评价和荟萃分析的首选报告条目× | 网络荟萃分析× | |
|---|---|---|
| 领域≠ | 荟萃分析 | 证据综合 |
| 方法族 | Process / pipeline | Process / pipeline |
| 起源年份≠ | 2021 | 2002 |
| 提出者≠ | Matthew Page et al. (PRISMA 2020) | Lumley (2002) |
| 类型≠ | Reporting guideline and flow diagram | Method |
| 开创性文献≠ | Page, M. J., et al. (2021). The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ, 372, n71. DOI ↗ | Lumley, T. (2002). Network meta-analysis for indirect treatment comparisons. Statistics in Medicine, 21(16), 2313–2324. DOI ↗ |
| 别名≠ | Preferred Reporting Items for Systematic Reviews and Meta-Analyses, PRISMA 2020, PRISMA checklist, Sistematik Derleme Raporlama Kılavuzu | Mixed Treatment Comparison, MTC, Indirect Comparison Meta-Analysis |
| 相关≠ | 2 | 1 |
| 摘要≠ | PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) is a standardized reporting guideline designed to improve the transparency and completeness of systematic reviews and meta-analyses. Introduced in its current form by Page et al. in 2021 as PRISMA 2020, it provides a 27-item checklist and a four-phase flow diagram that together ensure every stage of a review — from database searching through final inclusion — is documented and reproducible. | Network meta-analysis (NMA) is a systematic method for comparing multiple interventions simultaneously within a single analytical framework, incorporating both direct evidence (head-to-head trials) and indirect evidence (comparisons via common comparators). First formalized by Lumley in 2002, NMA allows researchers to rank treatments and quantify comparative effectiveness even when some treatment pairs have never been directly studied. |
| ScholarGate数据集 ↗ |
|
|